[Advances in the treatment of parkinsonism].
D000547:Amantadine / Q000627:therapeutic use*; D001921:Brain / Q000201:enzymology / Q000378:metabolism; D002462:Cell Membrane; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004296:Dopa Decarboxylase / Q000378:metabolism; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D013238:Stereotaxic Techniques; D013378:Substantia Nigra / Q000187:drug effects; D014839:Vomiting / Q000139:chemically induced
D004295:Dihydroxyphenylalanine; D000547:Amantadine; D004296:Dopa Decarboxylase
Postepy w leczeniu parkinsonizmu.